Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Brian JAMIESON |
|---------------------|----------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct |
|--|--|
| Nature of indirect interest | Director and a related party interest as |
| (including registered holder) | beneficiaries of shares held by Brians |
| Note: Provide details of the circumstances giving rise to the relevant interest. | Maserati Pty Ltd |
| Date of change | 18/12/2017 |
| No. of securities held prior to change | 743,229 |
| 2 | Direct – 557,833 |
| | Indirect – 185,396 |
| Class | FPO |
| | |
| Number acquired | 10,727 |
| Number disposed | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and estimated valuation | \$10,297.92 |
| No. of securities held after change | 753,956 |
| | Direct – 568,560 |
| | Indirect – 185,396 |
| Nature of change | Shares purchased under NED's Share Plan |
| Example: on-market trade, off-market trade, exercise of | |
| options, issue of securities under dividend reinvestment | |
| plan, participation in buy-back | |

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | |
|--|----|
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |
| Part 3 – ⁺ Closed period | , |
| Were the interests in the securities | No |

P

| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
|---|----|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3YChange of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Kathryn SPARGO |
|---------------------|----------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct |
|--|---|
| Nature of indirect interest | Self-managed superannuation fund of |
| (including registered holder) | Director Spargo Super Pty Ltd (atf Spargo |
| Note: Provide details of the circumstances giving rise to the relevant interest. | Super Fund) |
| Date of change | 18/12/2017 |
| No. of securities held prior to change | 112,003 |
| | Direct – 32,003 |
| | Indirect – 80,000 |
| | · |
| Class | FPO |
| Number acquired | 5,160 |
| Number disposed | |
| Value/Consideration | \$4,953.60 |
| Note: If consideration is non-cash, provide details and | |
| estimated valuation | 11712 |
| No. of securities held after change | 117,163 |
| | Direct – 37,163 |
| | Indirect – 80,000 |
| Nature of change | Shares purchased under NED's Share Plan |
| Example: on-market trade, off-market trade, exercise of | |
| options, issue of securities under dividend reinvestment | |
| plan, participation in buy-back | |

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | |
|--|--|
| Nature of interest | |
| Name of registered holder | |
| <u>e</u> | |
| (if issued securities) | |
| Date of change | |
| | |
| No. and class of securities to which | |
| interest related prior to change | |
| Note: Details are only required for a contract | |
| in relation to which the interest has changed | |
| in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Interest disposed | |
| | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide | |
| details and an estimated valuation | |
| | |
| Interest after change | |
| J | |
| | |

Part 3 – *Closed period

| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
|---|----|
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

Rule 3.19A.2

Appendix 3Y Page 4 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/201

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | David BAYES |
|---------------------|-------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Indirect |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change | Self-managed superannuation fund of Director, Talbot Holdings (VIC) Pty Ltd (atf Bayes Super Fund). Investment trust of Director, Kateco (VIC) Pty Ltd (atf David Bayes Investment Trust). 18/12/2017 |
| No. of securities held prior to change | 319,499 Direct – 104,644 Indirect – 214,855 |
| Class | FPO FPO |
| Number acquired | 6,613 |
| Number disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$6,348.48 |
| No. of securities held after change | 326,112 Direct – 104,644 Indirect – 221,468 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | |
|---|----|
| Nature of interest | |
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |
| Part 3 – ⁺ Closed period | |
| Were the interests in the securities or contracts detailed above traded during a *closed period where | No |
| prior written clearance was | |

required?

provided?

If so, was prior written clearance provided to allow the trade to proceed during this period?

If prior written clearance was provided, on what date was this

Appendix 3Y Page 6 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | David Gerald MANUEL |
|---------------------|---------------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct |
|--|---|
| Nature of indirect interest | |
| (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest | |
| Date of change | 18/12/2017 |
| No. of securities held prior to change | 206,213 Direct – 206,213 |
| Class | FPO |
| Number acquired | 4,979 |
| Number disposed | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and estimated valuation | \$4,779.84 |
| No. of securities held after change | 211,192 |
| | Direct – 211,192 |
| Nature of change | Shares purchased under NED's Share Plan |
| Example: on-market trade, off-market trade, exercise of | |
| options, issue of securities under dividend reinvestment | |
| plan, participation in buy-back | |

+ See chapter 19 for defined terms.

Detail of contract

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Nature of interest | |
|--|----|
| Name of registered holder (if issued securities) | |
| Date of change | |
| No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |
| Part 3 – *Closed period | |
| Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required? | No |
| If so, was prior written clearance provided to allow the trade to proceed during this period? | |
| If prior written clearance was provided, on what date was this provided? | |

Appendix 3Y Page 8 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/2011

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Raymond Mark GUNSTON |
|---------------------|----------------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to | |
| Date of change | 18/12/2017 |
| No. of securities held prior to change | 205,263 Direct – 205,263 |
| Class | FPO |
| Number acquired | 6,795 |
| Number disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$6,523.20 |
| No. of securities held after change | 212,058 Direct – 212,058 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

+ See chapter 19 for defined terms.

Detail of contract

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Nature of interest | |
|---|----|
| | |
| Name of registered holder | |
| (if issued securities) | |
| Date of change | |
| No. and class of securities to which | |
| interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide details and an estimated valuation | |
| Interest after change | |
| Part 3 – *Closed period | |
| Were the interests in the securities | No |
| or contracts detailed above traded during a *closed period where | |
| prior written clearance was required? | |
| If so, was prior written clearance | |
| provided to allow the trade to | |
| proceed during this period? | |

Rule 3.19A.2

provided?

If prior written clearance was provided, on what date was this

Appendix 3Y Page 10 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

| Name of entity | SIGMA HEALTHCARE LIMITED |
|----------------|--------------------------|
| ABN | ABN 15 088 417 403 |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| Name of Director | Christine BARTLETT |
|---------------------|--------------------|
| Date of last notice | 3/10/2017 |

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Direct or indirect interest | Direct |
|---|---|
| Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. | |
| Date of change | 18/12/2017 |
| No. of securities held prior to change | 25,284 Direct – 25,284 |
| Class | FPO |
| Number acquired | 4,978 |
| Number disposed | |
| Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation | \$4,778.88 |
| No. of securities held after change | 30,262 Direct – 30,262 |
| Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Shares purchased under NED's Share Plan |

⁺ See chapter 19 for defined terms.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| Detail of contract | |
|--|-----|
| Nature of interest | |
| Name of registered holder | |
| (if issued securities) | |
| Date of change | |
| No. and class of securities to which | |
| interest related prior to change | |
| Note: Details are only required for a contract | |
| in relation to which the interest has changed | |
| Interest acquired | |
| Interest disposed | |
| Value/Consideration | |
| Note: If consideration is non-cash, provide | |
| details and an estimated valuation | |
| Interest after change | |
| art 3 – ⁺ Closed period | |
| Were the interests in the securities | No |
| or contracts detailed above traded | INU |
| | |
| during a +closed period where | |
| prior written clearance was | |

required?

provided?

If so, was prior written clearance provided to allow the trade to

If prior written clearance was provided, on what date was this

proceed during this period?

Appendix 3Y Page 12 01/01/2011

⁺ See chapter 19 for defined terms.